Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin Prophylaxis for Recurrent C. difficile Infections During Systemic Antibiotics
NCT06979609Phase 3Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vancomycin in Clostridioides difficile infection (CDI), sponsored by McGill University Health Centre. Started Nov 2025; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06979609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979609.